Menopause hormone therapy may support weight loss and bone health, while newer data ease dementia concerns

Overview of Menopause

Menopause is a natural life stage marked by declining ovarian hormone production, particularly estrogen, and is often accompanied by symptoms that can significantly affect quality of life. Hot flashes, sleep disturbance, vaginal dryness, and mood changes are among the most common complaints. Menopausal hormone therapy, also called hormone replacement therapy, remains one of the most effective options for symptom control. Although its use has long been clouded by safety concerns, the discussion is evolving as newer evidence suggests that, for appropriately selected women, hormone therapy may be safer and more beneficial than previously believed.

Hormone therapy and dementia risk

One of the major longstanding concerns around menopausal hormone therapy has been its possible association with dementia. However, a large 2025 review found no evidence that menopause hormone therapy either increased or decreased dementia risk in postmenopausal women. The review pooled data from 10 studies involving more than 1 million participants, providing one of the broadest assessments to date on this question.

This updated evidence aligns with a major regulatory shift in the United States. In November 2025, the FDA initiated the removal of boxed warnings related to cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products, and in February 2026 announced the first approved labeling changes for several products. The endometrial cancer warning for systemic estrogen-alone products was not removed. Taken together, these changes suggest that the older risk narrative surrounding hormone therapy is being reconsidered in light of newer evidence and a more individualized approach to patient selection.

Hormone therapy and weight control

Interest in menopausal hormone therapy has recently expanded beyond symptom relief to include possible metabolic benefits. In January 2026, researchers reported that postmenopausal women using GLP-1 agonist medication with menopausal hormone therapy achieved about 35% greater weight loss than women using GLP-1 agonist monotherapy.

The authors emphasized that the study was observational, meaning it cannot prove that hormone therapy directly caused the greater weight loss. Still, the results raise the possibility that menopausal status and hormone therapy use may influence response to anti-obesity pharmacotherapy. This could eventually support a more personalized treatment strategy for midlife women with obesity.

While these findings are promising, prospective trials are still needed before hormone therapy can be viewed as a weight-management intervention in its own right. At present, the data are best interpreted as hypothesis-generating rather than practice-changing.

Hormone therapy and osteoporosis risk

Bone health is another area where earlier treatment may matter. Estrogen decline after menopause accelerates bone loss, increasing the risk of osteoporosis and fractures over time. At the AAOS 2026 Annual Meeting, researchers presented data from a large real-world study of 137,484 postmenopausal women under the age of 60. Women who did not start hormone therapy within one year of menopause onset had an 18% higher risk of osteoporosis at 5 years compared with those who initiated treatment earlier.

These findings support the idea that timing may be clinically important. For women who are eligible for menopausal hormone therapy and are also concerned about future bone loss, starting treatment around the onset of menopause may offer an advantage over delaying therapy until osteoporosis is already established. However, these results were presented at a scientific meeting and should still be interpreted with appropriate caution pending further peer-reviewed validation.

Conclusion

Recent evidence suggests that menopausal hormone therapy may offer benefits beyond symptom relief. Newer data indicate no clear increase in dementia risk, while emerging research points to possible advantages in weight management and bone protection, particularly when therapy is started early in eligible women. Even so, treatment decisions should remain individualized, balancing symptom burden, age, timing since menopause onset, and each patient’s overall risk profile.

Source

1. MedicalNewsToday – access March 2026
2.  https://doi.org/10.1016/S3050-5038(25)00145-1
3. https://doi.org/10.1016/j.lanhl.2025.100803
4.  https://doi.org/10.1515/biol-2022-0759